Coherus Oncology, Inc. (CHRS)

Coherus Oncology Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	154.97	28.51	-237.89	-291.75	-287.1	132.24
Depreciation & Amortization	4.06	5.28	3.79	3.7	3.45	2.89
Other Amortization	4.16	4.16	2.41	6.43	4.26	3.48
Loss (Gain) From Sale of Assets	-176.59	-176.59	-	-	-	-
Asset Writedown & Restructuring Costs	2.15	10.57	-	-	3.21	-
Loss (Gain) From Sale of Investments	-	-	-	-	1.1	-
Stock-Based Compensation	20.57	27.8	43.11	50.74	51.36	38.16
Other Operating Activities	30.18	23.94	50.53	69.02	143.93	12.02
Change in Accounts Receivable	158.22	149.35	-150.68	13.05	34.06	-15.22
Change in Inventory	-22.45	-31.95	-46.73	-47.35	-6.25	-38.36
Change in Accounts Payable	-8.13	-3.94	23.76	-4.55	0.87	-9.82
Change in Other Net Operating Assets	-95.29	-57.57	136.83	-40.41	13.68	28.75
Operating Cash Flow	-90.19	-20.44	-174.88	-241.12	-37.43	154.15
Operating Cash Flow Growth	-	-	-	-	-	443.63%
Capital Expenditures	-	-	-	-	-1.29	-7.23
Sale of Property, Plant & Equipment	-	-	-	-	-	0.18
Cash Acquisitions	-	-	7	-	-	-
Divestitures	227.82	227.82	-	-	-	-
Sale (Purchase) of Intangibles	-12.5	-12.5	-	-35	-	-7.5
Investment in Securities	-87.93	14.89	138.14	-127.38	-1.12	0.16
Other Investing Activities	249.99	0.11	-0.49	-4.47	-136	-
Investing Cash Flow	377.38	230.32	144.64	-166.85	-138.41	-14.4
Long-Term Debt Issued	-	36.98	-	240.68	-	222.16
Long-Term Debt Repaid	-	-260.39	-	-190.75	-	-
Net Debt Issued (Repaid)	-233.19	-223.41	-	49.93	-	222.16
Issuance of Common Stock	0.72	2.67	74.22	9.37	54.3	21.23
Repurchase of Common Stock	-0.29	-2.48	-3.59	-3.74	-1.75	-0.88
Other Financing Activities	-48.8	36.24	-1.03	-1.23	-0.67	-18.56
Financing Cash Flow	-281.56	-186.97	69.6	54.33	51.88	223.95
Net Cash Flow	5.64	22.91	39.36	-353.65	-123.96	363.69
Free Cash Flow	-90.19	-20.44	-174.88	-241.12	-38.72	146.91
Free Cash Flow Growth	-	-	-	-	-	453.70%
Free Cash Flow Margin	-32.47%	-7.66%	-67.98%	-114.25%	-11.86%	30.88%
Free Cash Flow Per Share	-0.78	-0.18	-1.86	-3.11	-0.51	1.76
Cash Interest Paid	25.38	25.38	37.86	34.88	18.68	16.96
Cash Income Tax Paid	-	-0.11	-0.12	0.04	1.22	3.95
Levered Free Cash Flow	29.65	41.59	-69.86	-186.86	-60.97	83.04
Unlevered Free Cash Flow	41.17	54.4	-46.93	-173	-50.88	92.78
Change in Working Capital	32.36	55.89	-36.83	-79.26	42.36	-34.65

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q